Business
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study","length":128,"tagName":"p"},{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion.","length":538,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/992ee1ec6e5487355ec56dc328b9c871"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q.szcv0IermzRF0faJsY_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2OA--/https://media.zenfs.com/en/accesswire.ca/992ee1ec6e5487355ec56dc328b9c871","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_QbeusKQqaxxVVpDOb4QSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIw/https://media.zenfs.com/en/accesswire.ca/992ee1ec6e5487355ec56dc328b9c871","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/533b96d0-59ce-4814-81c7-ddadd2e900f0/igc-pharma-inc-2026.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The addition comes as the CALMA trial advances through its final phase of enrollment and reflects the Company's continued focus on strengthening site quality, expanding patient access, and supporting consistent execution across its clinical network. Kerwin Medical Center brings focused experience in Alzheimer's disease, mild cognitive impairment, frontotemporal dementia, and related neurodegenerative conditions.","length":423,"tagName":"p"},{"type":"text","content":"The site's Principal Investigator is Dr. Alka Khera, M.D., a behavioral neurologist with experience conducting Alzheimer's clinical trials. IGC Pharma believes that adding specialized behavioral neurology expertise in a major U.S. metropolit...